Schnitzler syndrome refractory to anakinra: successful treatment with canakinumab

Schnitzler syndrome refractory to anakinra: successful treatment with canakinumab

Schnitzler syndrome (SchS) is a rare autoimmune and inflammatory disease mediated by interleukin-1 beta (IL-1β). Recurrent monoclonal gammopathy and chronic urticarial rash are the symptoms required for diagnosis according to the Strasbourg criteria. The low prevalence of this syndrome (around 300 c...

Full description

Bibliographic Details
Main Authors: Angel Luis Salcedo-Mingoarranz, María Dorado-Fernández, Sofía García-Martínez, Paz Collado-Ramos, Nicolás Silvestre-Torner
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Journal of Dermatological Treatment
Subjects:
anakinra
autoinflammatory
canakinumab
schnitzler syndrome (schs)
Online Access:http://dx.doi.org/10.1080/09546634.2023.2242705

Internet

http://dx.doi.org/10.1080/09546634.2023.2242705

Similar Items